These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Integrating aprepitant and palonosetron into clinical practice: a role for the new antiemetics. Viale PH Clin J Oncol Nurs; 2005 Feb; 9(1):77-84. PubMed ID: 15751501 [TBL] [Abstract][Full Text] [Related]
4. Chemotherapy-induced nausea and vomiting: state of the art in 2006. Schwartzberg L J Support Oncol; 2006 Feb; 4(2 Suppl 1):3-8. PubMed ID: 16499138 [TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer. Kaushal J; Gupta MC; Kaushal V; Bhutani G; Dhankar R; Atri R; Verma S Singapore Med J; 2010 Nov; 51(11):871-5. PubMed ID: 21140114 [TBL] [Abstract][Full Text] [Related]
6. Palonosetron (Aloxi) for prevention of nausea and vomiting due to cancer chemotherapy. Med Lett Drugs Ther; 2004 Mar; 46(1179):27-8. PubMed ID: 15057189 [No Abstract] [Full Text] [Related]
7. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents. Navari RM J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652 [TBL] [Abstract][Full Text] [Related]
9. [Advances in the prevention and therapy of common chemotherapy-induced side effects]. Schenk T; Scheithauer W Dtsch Med Wochenschr; 1993 Jun; 118(22):831-7. PubMed ID: 8504725 [No Abstract] [Full Text] [Related]
10. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Rubenstein EB Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194 [TBL] [Abstract][Full Text] [Related]
16. Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting. Ruhlmann C; Herrstedt J Expert Rev Anticancer Ther; 2010 Feb; 10(2):137-48. PubMed ID: 20131990 [TBL] [Abstract][Full Text] [Related]
17. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response. Massa E; Astara G; Madeddu C; Dessì M; Loi C; Lepori S; Mantovani G Crit Rev Oncol Hematol; 2009 Apr; 70(1):83-91. PubMed ID: 18723369 [TBL] [Abstract][Full Text] [Related]
18. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. Grote T; Hajdenberg J; Cartmell A; Ferguson S; Ginkel A; Charu V J Support Oncol; 2006 Sep; 4(8):403-8. PubMed ID: 17004515 [TBL] [Abstract][Full Text] [Related]
20. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting. Hajdenberg J; Grote T; Yee L; Arevalo-Araujo R; Latimer LA J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]